ALK and neoplasm: Although only 2.4 % of the initial number of patients who were eligible for molecular analysis did not have adequate tissue/tumor cells for any tests, no additional adequate material was available for ALK immunohistochemistry in 8.6 % of the tested samples, which stresses the importance of proper handling of tumor samples in order to have enough for all necessary analyses.